Effect of high-dose N-acetylcysteine on exacerbations and lung function in patients with mild-to-moderate COPD: a double-blind, parallel group, multicentre randomised clinical trial.

Primary outcomes The incidence of exacerbations was lower in the N -acetylcysteine group than in the placebo group, but this difference did not reach statistical significance (0.65 [95% CI, 0.56–0.76] vs. 0.72 [95% CI, 0.64–0.84] per patient-year; relative risk [RR], 0.90; 95% CI, 0.80–1.02; P = 0.10) (Fig. 2 ).

also in 111,027 other papers